GlobalData on MSN19d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...
Medical News Today12d
Nucala administration
Nucala (mepolizumab) is a brand-name subcutaneous injection that comes in different forms. Depending on which form you’re prescribed, you or your doctor will administer the injection. Nucala ...
Medscape3d
New ACG Guideline on EoE Reflects Over a Decade of Advances in Diagnosis and Management
The guidelines support use of PPIs, dietary therapy, and biologics for EoE, and stress the importance of addressing both the ...
pharmaphorum1d
GSK says Nucala hits the target in new COPD trial
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...
pharmaphorum20h
GSK’s twice-yearly asthma drug clears two phase 3 trials
GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company ...
Pharmaceutical Technology4d
Mepolizumab by GSK for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
Mepolizumab is under clinical development by GSK and currently in Phase III for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase III drugs for Chronic Obstructive Pulmonary ...
thorax.bmj28d
Mepolizumab in corticosteroid-resistant eosinophilic asthma
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
Future Market Insights7d
Global Nasal Allergy Treatment Market to Reach USD 13.3 Billion by 2033 at a CAGR of 6.7% | Data by Future Market Insights, Inc.
According to Future Market Insights, the global nasal allergy treatment market is poised for substantial growth, with its valuation expected to double from USD 6.6 billion in 2022 to USD 13.3 billion ...
Pharmaceutical Technology19d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
GSK’s Nucala was approved in the US for severe asthma with an eosinophilic phenotype treatment. Credit: MAXSHOT.PL / Shutterstock. The China National Medical Products Administration (NMPA) has ...
thorax.bmj28d
P15 Cost effectiveness of mepolizumab for severe eosinophilic asthma from the uk perspective
Introduction Severe asthma patients have limited therapeutic options. These patients remain at risk of exacerbations, their quality of life is negatively impacted and they place a significant burden ...
BMJ29d
Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities
Only a minority of patients with eosinophilic granulomatosis with polyangiitis (EGPA) can be weaned-off glucocorticoids (GC) using conventional treatment strategies. The development of biological ...